JP2021514665A5 - - Google Patents
Info
- Publication number
- JP2021514665A5 JP2021514665A5 JP2020547001A JP2020547001A JP2021514665A5 JP 2021514665 A5 JP2021514665 A5 JP 2021514665A5 JP 2020547001 A JP2020547001 A JP 2020547001A JP 2020547001 A JP2020547001 A JP 2020547001A JP 2021514665 A5 JP2021514665 A5 JP 2021514665A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- cells
- enucleated
- polypeptide
- exogenous
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862640530P | 2018-03-08 | 2018-03-08 | |
| US62/640,530 | 2018-03-08 | ||
| US201862660657P | 2018-04-20 | 2018-04-20 | |
| US62/660,657 | 2018-04-20 | ||
| US201862680490P | 2018-06-04 | 2018-06-04 | |
| US62/680,490 | 2018-06-04 | ||
| US201862692487P | 2018-06-29 | 2018-06-29 | |
| US62/692,487 | 2018-06-29 | ||
| US201862732050P | 2018-09-17 | 2018-09-17 | |
| US62/732,050 | 2018-09-17 | ||
| US201862757717P | 2018-11-08 | 2018-11-08 | |
| US62/757,717 | 2018-11-08 | ||
| PCT/US2019/021490 WO2019173798A1 (en) | 2018-03-08 | 2019-03-08 | Therapeutic cell systems and methods for treating cancer and infectious diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021514665A JP2021514665A (ja) | 2021-06-17 |
| JP2021514665A5 true JP2021514665A5 (enExample) | 2022-03-16 |
Family
ID=65904565
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020547001A Pending JP2021514665A (ja) | 2018-03-08 | 2019-03-08 | がんおよび感染症を処置するための治療用細胞系および方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11141433B2 (enExample) |
| EP (1) | EP3762422A1 (enExample) |
| JP (1) | JP2021514665A (enExample) |
| KR (1) | KR20200140279A (enExample) |
| CN (1) | CN112105723A (enExample) |
| AU (1) | AU2019232012A1 (enExample) |
| CA (1) | CA3093387A1 (enExample) |
| IL (1) | IL277159A (enExample) |
| MX (1) | MX2020009359A (enExample) |
| RU (1) | RU2020132924A (enExample) |
| SG (1) | SG11202008261WA (enExample) |
| WO (1) | WO2019173798A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| WO2019032628A1 (en) | 2017-08-07 | 2019-02-14 | The Regents Of The University Of California | GENERATING PLATFORM FOR SAFE CELLULAR THERAPEUTIC AGENTS |
| CN112105723A (zh) | 2018-03-08 | 2020-12-18 | 鲁比厄斯治疗法股份有限公司 | 用于治疗癌症和传染病的治疗性细胞系统和方法 |
| EP3891269A1 (en) * | 2018-12-03 | 2021-10-13 | Rubius Therapeutics, Inc. | Artificial antigen presenting cells including hla-e and hla-g molecules and methods of use |
| JP2022530130A (ja) | 2019-04-26 | 2022-06-27 | ルビウス セラピューティクス， インコーポレイテッド | 除核赤血球細胞を含む緩衝組成物 |
| IL288210B2 (en) | 2019-05-20 | 2026-03-01 | Cytune Pharma | Dosing regimens of IL-2/IL-15 beta-gamma receptor agonists for the treatment of cancer or infectious diseases |
| CN110777115B (zh) * | 2019-11-21 | 2020-08-21 | 北京启辰生生物科技有限公司 | 用于促进辅助T细胞产生TNF-α细胞因子的工程化DC细胞及方法 |
| JP2023512712A (ja) * | 2020-02-07 | 2023-03-28 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 除核細胞をバイオ操作するための方法および使用 |
| JP2023513263A (ja) * | 2020-02-10 | 2023-03-30 | ルビウス セラピューティクス， インコーポレイテッド | Ｈｌａ－ｇポリペプチドを含む操作された赤血球系細胞およびその使用方法 |
| CN111849896B (zh) * | 2020-07-31 | 2022-07-01 | 广东昭泰体内生物医药科技有限公司 | 一种car-nk细胞培养基及其应用 |
| WO2022090203A1 (en) | 2020-10-26 | 2022-05-05 | Cytune Pharma | IL-2/IL-15Rβү AGONIST FOR TREATING SQUAMOUS CELL CARCINOMA |
| EP4232068A1 (en) | 2020-10-26 | 2023-08-30 | Cytune Pharma | IL-2/IL-15RBetaGamma AGONIST FOR TREATING NON-MELANOMA SKIN CANCER |
| TW202241470A (zh) | 2021-01-08 | 2022-11-01 | 美商盧比亞斯治療公司 | 治療人類個體腫瘤之方法 |
| TW202241471A (zh) | 2021-01-08 | 2022-11-01 | 美商盧比亞斯治療公司 | 提高個體中NKp30陽性淋巴球的方法及其用途 |
| WO2022197548A1 (en) | 2021-03-14 | 2022-09-22 | Rubius Therapeutics, Inc. | Methods of increasing nkg2d-positive lymphocytes in a subject and uses thereof |
| US20240254445A1 (en) * | 2021-06-01 | 2024-08-01 | Vaxcell-Bio | Composition containing feeder cell for proliferating natural killer cell |
| TW202317179A (zh) | 2021-06-03 | 2023-05-01 | 美商盧比亞斯治療公司 | 在個體中治療ｈｐｖ１６－陽性或ｈｐｖ１６－相關的癌症之方法 |
| CN115595310A (zh) * | 2021-07-08 | 2023-01-13 | 中国医学科学院血液病医院（中国医学科学院血液学研究所）（Cn） | Nk细胞的滋养细胞、其制备方法和应用 |
| CN113599395B (zh) * | 2021-09-22 | 2022-08-12 | 郑州源创吉因实业有限公司 | 含有nk细胞的治疗癌症的药物组合物 |
| CN114113639B (zh) * | 2022-01-29 | 2022-04-19 | 北京大有天弘科技有限公司 | 一种血型抗体检测方法及其应用 |
| WO2023250484A2 (en) * | 2022-06-24 | 2023-12-28 | Emory University | Recombinant interleukin-37, chimeric antigen receptors, nucleic acids, and vectors encoding the same and uses in cancer therapies |
| JP2026503418A (ja) * | 2022-12-28 | 2026-01-29 | サイトナス セラピューティクス インコーポレイテッド | 癌を治療するための組成物及び方法 |
| EP4694916A1 (en) | 2023-04-14 | 2026-02-18 | SOTIO Biotech Inc. | Engineered immune cells for treating cancer in combination with il-2/il-15 receptor ?? agonists |
| CN116789795A (zh) * | 2023-06-21 | 2023-09-22 | 广州奥科生物医学科技有限公司 | 一种将外源过表达蛋白锚定细胞膜上的多肽及应用 |
| CN117304343B (zh) * | 2023-10-11 | 2024-05-07 | 北京景达生物科技有限公司 | Gpc3靶向的car-nk细胞的制备及其应用 |
| WO2025221669A1 (en) * | 2024-04-18 | 2025-10-23 | Promab Biotechnologies, Inc. | Fusion protein comprising il-12 and gm-csf |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4327710A (en) | 1980-06-18 | 1982-05-04 | The United States Of America As Represented By The Secretary Of Agriculture | Process for encapsulating additives in resealed erythrocytes for disseminating chemicals via the circulatory system |
| US4935223A (en) | 1988-08-04 | 1990-06-19 | Board Of Regents, The University Of Texas System | Labeled cells for use in imaging |
| DK0517986T3 (da) | 1991-06-14 | 1998-03-30 | Europ Communities | Transformerede erythrocytter, fremgangsmåde til fremstilling af samme og deres anvendelse i farmaceutiske præparater |
| EP0882448B1 (en) | 1997-05-05 | 2005-01-12 | DIDECO S.r.l. | Method of encapsulating biologically active agents within erythrocytes and apparatus therefor |
| US6495351B2 (en) | 2000-02-08 | 2002-12-17 | Gendel Limited | Loading system and method for using the same |
| DE10335833A1 (de) * | 2003-08-05 | 2005-03-03 | Curevac Gmbh | Transfektion von Blutzellen mit mRNA zur Immunstimulation und Gentherapie |
| US7288638B2 (en) | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
| NZ569541A (en) * | 2006-01-13 | 2012-05-25 | Us Gov Health & Human Serv | Codon optimized IL-15 and IL-15R-alpha genes for expression in mammalian cells |
| US20070243137A1 (en) | 2006-04-18 | 2007-10-18 | Nanoprobes, Inc. | Cell and sub-cell methods for imaging and therapy |
| NZ599338A (en) * | 2007-06-27 | 2013-11-29 | Marinepolymer Tech Inc | Complexes of il-15 and il-15ralpha and uses thereof |
| FR2919804B1 (fr) * | 2007-08-08 | 2010-08-27 | Erytech Pharma | Composition et vaccin therapeutique anti-tumoral |
| US20100040546A1 (en) | 2008-08-13 | 2010-02-18 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Biological targeting compositions and methods of using the same |
| MX337040B (es) | 2010-09-09 | 2016-02-09 | Pfizer | Moleculas de union a 4-1bb. |
| EP2686420B1 (en) | 2011-03-18 | 2017-03-01 | New York Blood Center, Inc. | Megakaryocyte and platelet production from stem cells |
| EP2994491A4 (en) | 2013-05-10 | 2016-12-07 | Whitehead Inst Biomedical Res | IN VITRO PREPARATION OF ERYTHROCYTES WITH SORTASE-PROOF PROTEINS |
| WO2014183066A2 (en) | 2013-05-10 | 2014-11-13 | Whitehead Institute For Biomedical Research | Protein modification of living cells using sortase |
| CA2930665A1 (en) | 2013-11-18 | 2015-05-21 | Rubius Therapeutics, Inc. | Synthetic membrane-receiver complexes |
| MA39819A (fr) | 2014-04-01 | 2017-02-08 | Rubius Therapeutics Inc | Méthodes et compositions d'immunomodulation |
| CA2945388A1 (en) * | 2014-04-23 | 2015-10-29 | Board Of Regents, The University Of Texas System | Chimeric antigen receptors (car) for use in therapy and methods for making the same |
| EP3390643B8 (en) * | 2015-12-18 | 2023-08-02 | OncoSec Medical Incorporated | Plasmid constructs for heterologous protein expression and methods of use |
| KR20180096789A (ko) | 2016-01-11 | 2018-08-29 | 인히브릭스, 인크. | 다가 및 다중특이적 41bb-결합 융합 단백질 |
| SI3402491T1 (sl) * | 2016-01-11 | 2022-05-31 | Rubius Therapeutics, Inc. | Sestavki in postopki v zvezi z multimodalnimi terapevtskimi celičnimi sistemi za indikacije raka |
| MX2019000205A (es) | 2016-07-07 | 2019-09-23 | Rubius Therapeutics Inc | Composiciones y metodos relacionados con sistemas celulares terapeuticos que expresan arn exogeno. |
| CN106755107B (zh) * | 2016-11-22 | 2019-10-01 | 上海健信生物医药科技有限公司 | 一种car新分子及其在肿瘤治疗中的应用 |
| US20180153989A1 (en) | 2016-12-02 | 2018-06-07 | Rubius Therapeutics, Inc. | Compositions and methods related to cell systems for penetrating solid tumors |
| CN110520522A (zh) | 2017-02-17 | 2019-11-29 | 鲁比厄斯治疗法股份有限公司 | 功能化红系细胞 |
| WO2019036855A1 (en) | 2017-08-21 | 2019-02-28 | Adagene Inc. | Anti-cd137 molecules and use thereof |
| CN112105723A (zh) | 2018-03-08 | 2020-12-18 | 鲁比厄斯治疗法股份有限公司 | 用于治疗癌症和传染病的治疗性细胞系统和方法 |
-
2019
- 2019-03-08 CN CN201980030291.XA patent/CN112105723A/zh active Pending
- 2019-03-08 KR KR1020207029027A patent/KR20200140279A/ko not_active Withdrawn
- 2019-03-08 EP EP19713277.2A patent/EP3762422A1/en not_active Withdrawn
- 2019-03-08 WO PCT/US2019/021490 patent/WO2019173798A1/en not_active Ceased
- 2019-03-08 JP JP2020547001A patent/JP2021514665A/ja active Pending
- 2019-03-08 AU AU2019232012A patent/AU2019232012A1/en not_active Withdrawn
- 2019-03-08 US US16/297,540 patent/US11141433B2/en not_active Expired - Fee Related
- 2019-03-08 RU RU2020132924A patent/RU2020132924A/ru unknown
- 2019-03-08 MX MX2020009359A patent/MX2020009359A/es unknown
- 2019-03-08 SG SG11202008261WA patent/SG11202008261WA/en unknown
- 2019-03-08 CA CA3093387A patent/CA3093387A1/en active Pending
-
2020
- 2020-09-06 IL IL277159A patent/IL277159A/en unknown
-
2021
- 2021-09-27 US US17/486,537 patent/US20220088076A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021514665A5 (enExample) | ||
| RU2020132924A (ru) | Терапевтические клеточные системы и способы лечения рака и инфекционных заболеваний | |
| JP6709549B2 (ja) | Ｔ細胞の機能増強方法 | |
| KR102719575B1 (ko) | 신규의 세포 태그의 발현 | |
| JP2024138280A5 (enExample) | ||
| US5962320A (en) | Engineered antigen presenting cells and methods for their use | |
| JP2019517267A5 (enExample) | ||
| CN111566201A (zh) | 使用用于表达嵌合抗原受体(car)或转基因t细胞受体(tcr)的病毒载体转导细胞的方法 | |
| JP2021525534A5 (enExample) | ||
| JP2022520871A5 (enExample) | ||
| RU98111622A (ru) | Противоопухолевая вакцина и способ ее получения | |
| CN114127287A (zh) | 乙酰胆碱受体嵌合自身抗体受体细胞的组合物和方法 | |
| JP2024050551A (ja) | マウス定常領域を伴うｔｃｒを発現する細胞を選択的に増幅するための方法 | |
| EP4041869A1 (en) | Composition for reprogramming cells into plasmacytoid dendritic cells or interferon type i-producing cells, methods and uses thereof | |
| JP2022512540A5 (enExample) | ||
| EP4524149A1 (en) | Use of antigen short peptide in screening drug for treating hpv-related diseases and tcr screened by same | |
| CN117106061B (zh) | 靶向巨细胞病毒抗原的tcr和表达其的t细胞及应用 | |
| CN112940108A (zh) | 识别ebv抗原的t细胞受体以及该t细胞受体的应用 | |
| CN114555815A (zh) | T细胞受体及其使用方法 | |
| CN111499766B (zh) | 针对慢性淋巴细胞白血病的免疫效应细胞、其制备方法和应用 | |
| EP4524150A1 (en) | Use of antigen short peptide in screening of drug for treating hpv-related disease, and tcr screened by antigen short peptide | |
| WO2025082236A1 (zh) | 识别ebv抗原的t细胞受体及其应用 | |
| US20250361294A1 (en) | Nucleic acid sequence encoding a chimeric antigen natural killer cell receptor (nk-car), polypeptide of said nk-car, vector comprising said nucleic acid sequence, in vitro method of obtaining an nk cell, use of said nucleic acid sequence, polypeptide or vector, and pharmaceutical composition | |
| WO2020190936A1 (en) | Chimeric antigen receptors directed to cells expressing the sodium taurocholate co-transporting receptor | |
| CN117736301B (zh) | 靶向巨细胞病毒pp65的TCR和表达其的T细胞及应用 |